318 related articles for article (PubMed ID: 27019372)
1. Targeting NEK2 as a promising therapeutic approach for cancer treatment.
Fang Y; Zhang X
Cell Cycle; 2016; 15(7):895-907. PubMed ID: 27019372
[TBL] [Abstract][Full Text] [Related]
2. Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects.
Shah D; Joshi M; Patel BM
Fundam Clin Pharmacol; 2022 Oct; 36(5):766-776. PubMed ID: 35338518
[TBL] [Abstract][Full Text] [Related]
3. Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.
Dana D; Das T; Choi A; Bhuiyan AI; Das TK; Talele TT; Pathak SK
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056661
[TBL] [Abstract][Full Text] [Related]
4. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
[TBL] [Abstract][Full Text] [Related]
5. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
Jeong AL; Lee S; Park JS; Han S; Jang CY; Lim JS; Lee MS; Yang Y
J Biol Chem; 2014 Jan; 289(1):28-40. PubMed ID: 24214971
[TBL] [Abstract][Full Text] [Related]
6. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
[TBL] [Abstract][Full Text] [Related]
7. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 inhibitors.
Wang H; Chen Y; Gu X; Xi J; Ren Z; Wang S; Duan Y; Li H; Zhu T; Du Y; Zhang X; Ma M
Bioorg Med Chem; 2020 Dec; 28(23):115775. PubMed ID: 32992252
[TBL] [Abstract][Full Text] [Related]
9. NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.
Kokuryo T; Yokoyama Y; Yamaguchi J; Tsunoda N; Ebata T; Nagino M
Anticancer Res; 2019 May; 39(5):2251-2258. PubMed ID: 31092416
[TBL] [Abstract][Full Text] [Related]
10. High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.
Wan H; Xu L; Zhang H; Wu F; Zeng W; Li T
J Physiol Biochem; 2021 Feb; 77(1):25-34. PubMed ID: 33201407
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
12. Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity.
Fang Y; Kong Y; Xi J; Zhu M; Zhu T; Jiang T; Hu W; Ma M; Zhang X
Oncotarget; 2016 Nov; 7(48):79327-79341. PubMed ID: 27764815
[TBL] [Abstract][Full Text] [Related]
13. Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins.
Cervenka I; Valnohova J; Bernatik O; Harnos J; Radsetoulal M; Sedova K; Hanakova K; Potesil D; Sedlackova M; Salasova A; Steinhart Z; Angers S; Schulte G; Hampl A; Zdrahal Z; Bryja V
Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9304-9. PubMed ID: 27486244
[TBL] [Abstract][Full Text] [Related]
14. Nek2 kinase in chromosome instability and cancer.
Hayward DG; Fry AM
Cancer Lett; 2006 Jun; 237(2):155-66. PubMed ID: 16084011
[TBL] [Abstract][Full Text] [Related]
15. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy.
Chuang SH; Lee YE; Huang LYL; Chen CK; Lai CL; Lin YH; Yang JY; Yang SC; Chang LH; Chen CH; Liu CW; Lin HS; Lee YR; Huang KP; Fu KC; Jen HM; Lai JY; Jian PS; Wang YC; Hsueh WY; Tsai PY; Hong WH; Chang CC; Wu DZ; Wu J; Chen MH; Yu KM; Chern CY; Chang JM; Lau JYN; Huang JJ
Eur J Med Chem; 2020 Apr; 191():112118. PubMed ID: 32113126
[TBL] [Abstract][Full Text] [Related]
16. NIMA related kinase 2 promotes gastric cancer cell proliferation
Fan WD; Chen T; Liu PJ
World J Gastroenterol; 2019 Jun; 25(23):2898-2910. PubMed ID: 31249448
[TBL] [Abstract][Full Text] [Related]
17. Cep68 can be regulated by Nek2 and SCF complex.
Man X; Megraw TL; Lim YP
Eur J Cell Biol; 2015; 94(3-4):162-72. PubMed ID: 25704143
[TBL] [Abstract][Full Text] [Related]
18. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
19. The Nek2 protein kinase: a novel regulator of centrosome structure.
Fry AM
Oncogene; 2002 Sep; 21(40):6184-94. PubMed ID: 12214248
[TBL] [Abstract][Full Text] [Related]
20. NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer.
Bai R; Yuan C; Sun W; Zhang J; Luo Y; Gao Y; Li Y; Gong Y; Xie C
Int J Biol Sci; 2021; 17(8):1995-2008. PubMed ID: 34131401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
